United Therapeutics (UTHR) and Intermountain Health announced the world’s first patient treated in a clinical study of a bioengineered external liver assist product called miroliverELAP. This study is the first human clinical trial of a manufactured organ alternative.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics concludes enrollment in ADVANCE OUTCOMES study
- Buy Recommendation for United Therapeutics Based on Strong Market Position and Growth Potential
- United Therapeutics: Strong Market Position and Growth Potential Amidst Emerging Competition
- United Therapeutics price target lowered to $315 from $321 at BofA
- Morning Movers: Insmed jumps, United Therapeutics falls after TPIP study results